Loading...
PASG logo

Passage Bio, Inc.NasdaqCM:PASG Stock Report

Market Cap US$17.2m
Share Price
US$5.22
US$12
56.5% undervalued intrinsic discount
1Y-13.6%
7D24.0%
Portfolio Value
​
View

Passage Bio, Inc.

NasdaqCM:PASG Stock Report

Market Cap: US$17.2m

Passage Bio (PASG) Stock Overview

A genetic medicines company, develops gene therapies for central nervous system diseases. More details

PASG fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Earnings have grown 27.6% per year over the past 5 years

Risk Analysis

Has less than 1 year of cash runway

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

PASG Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Passage Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Passage Bio
Historical stock prices
Current Share PriceUS$5.22
52 Week HighUS$20.00
52 Week LowUS$3.94
Beta1.38
1 Month Change-56.10%
3 Month Change-40.75%
1 Year Change-13.58%
3 Year Change-73.64%
5 Year Change-98.09%
Change since IPO-98.82%

Recent News & Updates

Recent updates

Analysis Article • Jan 07

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Sep 24

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Jun 11

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 27

We're Keeping An Eye On Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 13

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jun 23

We Think Passage Bio (NASDAQ:PASG) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Nov 13

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Oct 10

Passage appoints William Chou CEO

Genetic medicines company Passage (NASDAQ:PASG) appointed William Chou CEO and a board member, effective immediately. Chou, most recently, served as CEO of the clinical-stage biopharmaceutical company Aruvant Sciences. Chou replaces interim CEO Edgar Cale, who will resign from the post and continue in his role as general counsel and corporate secretary. Also, Maxine Gowen will step down as interim executive chairwoman following a brief transition period and will then continue to serve as chairwoman. Source: Press Release
Seeking Alpha • Aug 04

Passage Bio GAAP EPS of -$0.73 beats by $0.09

Passage Bio press release (NASDAQ:PASG): Q2 GAAP EPS of -$0.73 beats by $0.09. Cash, cash equivalents and marketable securities were $239.3M as of June 30, 2022, compared to $267.1M as of March 31, 2022. The company expects current cash and cash equivalents to fund operations into the second quarter of 2024.
Analysis Article • Jun 03

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 11

Passage Bio: Worth Keeping An Eye On

Not long ago, PASG was awarded a $1.2B enterprise value by the market. Though the company made progress, the vagaries of the market are such that it now trades at a negative enterprise value. I survey the company and its programs to find reasons to monitor its progress with the potential of investing in the future.
Analysis Article • Dec 15

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Aug 19

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Mar 08

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • Feb 01

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

The big shareholder groups in Passage Bio, Inc. ( NASDAQ:PASG ) have power over the company. Institutions often own...
Analysis Article • Dec 28

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

Shareholder Returns

PASGUS BiotechsUS Market
7D24.0%1.0%1.1%
1Y-13.6%40.3%26.7%

Return vs Industry: PASG underperformed the US Biotechs industry which returned 40.3% over the past year.

Return vs Market: PASG underperformed the US Market which returned 26.7% over the past year.

Price Volatility

Is PASG's price volatile compared to industry and market?
PASG volatility
PASG Average Weekly Movement20.5%
Biotechs Industry Average Movement10.7%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.1%

Stable Share Price: PASG's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: PASG's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201724Will Chouwww.passagebio.com

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington’s disease.

Passage Bio, Inc. Fundamentals Summary

How do Passage Bio's earnings and revenue compare to its market cap?
PASG fundamental statistics
Market capUS$17.19m
Earnings (TTM)-US$37.68m
Revenue (TTM)n/a
0.0x
P/S Ratio
-0.4x
P/E Ratio

Is PASG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PASG income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$37.68m
Earnings-US$37.68m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-11.75
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PASG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/15 22:57
End of Day Share Price 2026/05/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Passage Bio, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Gbolahan Amusa BenzChardan Capital Markets, LLC
Janani SundararajanChardan Capital Markets, LLC